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1.1. Abstract  
 
Candida genus species are opportunistic fungi causing candidiasis, whose prevalence is 
on a growing trend. C. albicans is the commonest yeast causing opportunistic fungal diseases in 
humans, whose pleomorphism, highly adaptability and biofilm formation are essential for its 
virulence and pathogenicity. Other remarkable species are C. glabrata and the emergent 
multidrug resistant C. auris.  
Main antifungals used for treatment of invasive candidiasis are azoles, whose target is 
14α-lanosterol demethylase; polyenes, that target ergosterol; pyrimidine analogues, which 
inhibit DNA and RNA biosynthesis; and echinocandins, inhibiting β-(1,3)-glucan synthase. An 
inappropriate usage or prolonged exposure to these toxic compounds have developed the 
emergence of multidrug resistance phenomenon. One of the most prominent mechanisms of 
antifungal resistance in Candida genus is the rapid efflux of incoming drugs via active transport, 
due to the overexpression of two main classes of plasma membrane efflux pumps: ABC and 
MFS transporters. In addition, entry constraints, genomic alterations and cell plasticity are other 
mechanisms of the resistance. 
Owing to the alarming life-threatening infections caused by Candida spp., several 
strategies have been found to reduce drug resistance. Some of them are the structure-based 
design of effective inhibitors of efflux, chemosensitization and design of new antifungal drugs. 
An effective antifungal stewardship programme and further investigation are urgently needed to 




It is universally acknowledged that fungal diseases, related with substantial human 
morbidity and mortality, entail a major global impact. Even though they are gaining worldwide 
attention due to their progressive increase, they still remain unappreciated. According to a 2019 
survey of 3,624 adults in the United States, there is a low public awareness of invasive fungal 
diseases. More than two thirds of the respondents had never heard about any of the fungal 
diseases that were listed and candidiasis showed the highest percentage of awareness, 24,6% 
(Benedict et al., 2020).  By way of illustration, it has been estimated that over a quarter of the 
world’s population have a fungal skin infection, three quarters of women suffer vulvovaginal 
candidiasis at least once during their lifetime and more than a million people yearly die due to 
invasive fungal infection (d’Enfert et al., 2021).  
Our preparedness to tackle those pathogens is hindered by the development of 
antifungal resistance. Since the introduction in both agriculture and modern medicine and 
widespread use of triazoles in early 1990s, Candida resistant spp. have become a serious health 
threat. Clinical breakpoints of resistance are developed for Candida spp., mostly derived from 
episodes of invasive candidiasis in non-neutropenic patients and mucosal candidiasis. However, 
in patients with less frequent opportunistic yeast or mold infections, breakpoints only derive 
from epidemiological cut-off values and pharmacokinetic and pharmacodynamic data from 
animal models (Kontoyiannis, 2017).  
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In the pandemic world we are living nowadays, candidiasis is taking an active role in 
patients hospitalized for COVID-19. Candida infections resistant to antifungal treatment have 
been described in patients diagnosed with that disease (Posteraro et al., 2020). An increased 
incidence of antimicrobial resistance may be attributed to the excess use of antimicrobial drugs 
during this coronavirus pandemic.  
 
1.3. Aim and objectives 
 
This bibliographic review is aimed to provide a deeper insight into the current situation 
and findings of Candida genus resistance to antifungals. For that purpose, the objectives that 
have been achieved are: 
1. Research, select and classify appropriate scientific reviews. Make citations and 
references using the reference management application Mendeley.  
2. Increase the knowledge of Candida genus main representatives and antifungal drugs 
used to treat candidiasis.  
3. Highlight the actual situation of resistance to antifungals focusing on Candida genus 
mechanisms. 
4. Analysis of strategies to bypass antifungal resistance and tolerance developed by 
Candida genus, thereby contributing to public awareness of their urgent need.    
 




Yeasts are eukaryotic unicellular microfungi that along with molds belong to Fungi 
Kingdom. All members of this kingdom are comprised by not only a well-defined nucleus, 
mitochondria, Golgi bodies and endoplasmic reticulum, but also distinguishable features like a 
rigid cell wall containing chitin, glucan and unlike animals, ergosterol, its major sterol 
component of membranes. As opposed to molds that replicate either sexual or asexually, yeasts 
mostly replicate asexually by budding or fission. Curiously, for dimorphic fungi it is possible to 
assume both morphologies, yeast form in human tissues (except Coccidioides) and mold form in 
nature (Murray, 2018). 
These microbes are widespread in the natural environment and have been studied as 
eukaryotic models and exploited biotechnologically. Nonetheless, they pose a threat in our 
health considering they are among the most prominent disease-causing fungi.  
 
2.2. Candida genus 
 
The largest group of pathogenic fungi are ascomycetous yeasts, most of which belong to 
the anamorphic genus Candida. Candida spp. are opportunistic fungi causing candidiasis, 
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whose prevalence is on a growing trend. In fact, it is the third-to-fourth most recurrent 
nosocomial infection in US and worldwide hospitals  (Prasad, 2017).  
There is a paucity of rapid diagnostic assays for invasive candidiasis and it is usually 
diagnosed by routine cultures of blood, urine tissue and other body fluids that have a low 
sensitivity. When mannan is found, a characteristic polysaccharide of Candida cell wall, an 
invasive candidiasis is suggested. Besides, viable or dead fungal elements can be detected in 
tissue sections by fluorescent antibody microscopy (Murray, 2018). Nevertheless, there is a 
scarcity of suitable diagnostic techniques to identify resistant species. Regarding treatment, it 
depends on the immunological status of patients, its location and the severity of the infection. 
Candida infection is also related with medical devices (Kojic and Darouiche, 2004). 
On top of that, the situation is worsening by the emergence of multidrug resistant 
species of Candida. The US Center of Disease Control and Prevention (CDC) report published 
in 2019 estimates 34,800 cases and 1,700 deaths associated with drug-resistant Candida spp.  
(Centers for Disease Control and Prevention, 2019).   
 
2.2.1. Candida albicans 
 
Candida albicans (C. albicans), known as a model system of pathogenic fungi, is the 
commonest yeast causing opportunistic fungal diseases in humans and its economic impact and 
associated mortality challenge the intensive care units worldwide. It is considered both a 
commensal and opportunistic pathogen that produces infections whenever the immune system 
of the host is weakened or its microbiota becomes disturbed (Costa-de-oliveira and Rodrigues, 
2020). It colonizes humans and other warm-blooded animals’ mucosa producing endogenous 
infections in which it moves from normally colonized mucosal surfaces to the blood or other 
normally sterile locations. Exogenous infections can also occur in hospital  (Murray, 2018). 
Once in the mucosa, it specially resides in the conjunctival flora and in the gastrointestinal and 
genitourinary tracts (Pristov and Ghannoum, 2019). The foremost virulence factors of this yeast 
are yeast-to-mycelia morphological transformation, biofilm formation and production of 
secretory hydrolytic enzymes, particularly aspartic proteases and phospholipases (Prasad, 2017).  
Genome plasticity is a hallmark of C. albicans regarding fungal pathogenicity. Its 
successful infections are due to its pleomorphism, which is essential for its virulence and 
implies switching among different morphological phenotypes, from yeast to hyphal or 
pseudohyphal form (Costa-de-oliveira and Rodrigues, 2020). Hyphae formation, involved in 
adhesion to and invasion of host cells and tissues, is correlated with the upregulation of ALS3 
and ECE1 genes, which are involved in pathogenicity processes like invasion, iron acquisition 
and host damage. These virulence-associated genes have been shown to be regulated by the 
transcription factor Ahr1 and the global repressor Tup1, which is a crucial antagonist of hyphal 
formation in C. albicans (Ruben et al., 2020). On top of that, this pathogen is highly adaptable, 
being able to develop resistance after a prolonged exposure to antifungals and thus, making the 
choice of medicines increasingly limited (Costa-de-oliveira and Rodrigues, 2020). 
The medical impact of C. albicans depends on its ability to thrive as a biofilm on either 
biotic or abiotic surfaces. Biofilms, which are closely packed communities of cells, act as a 
physical barrier, preventing in some way drugs from reaching the underlying cells. Therefore, it 
leads to the enhancement of its virulence potential and to a higher resistance to antifungals and 
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the immune system than the planktonic forms, as it is able to withstand high antifungal 
concentrations (Prasad, 2017). The ability of C. albicans to form hyphae, the capacity of these 
hyphae to adhere to each other and to surfaces or host cells, and the dispersal of cells within a 
biofilm into the environment are critical for normal biofilm development and maintenance 
(Nobile and Johnson, 2015). So as to provide support and protection to the cells embedded 
within biofilms, thus contributing to biofilm drug resistance, biofilms are encased in an 
extracellular matrix (Prasad, 2017). Of note, once biofilms are formed on an implanted medical 
device, they can seed disseminated bloodstream infections and lead to invasive systemic 
infections (Nobile and Johnson, 2015). 
 
2.2.2. Other members of Candida genus 
 
As well as C. albicans, other Candida species categorised as non-albicans Candida 
(NAC) spp. can infect both healthy individuals and immunocompromised patients. Among 
them, some clinically important NAC spp. are Candida glabrata (C. glabrata), Candida 
parapsilosis (C. parapsilosis), Candida tropicalis (C. tropicalis), Candida guilliermondii (C. 
guilliermondii), Candida krusei (C. krusei) or Candida auris (C. auris). Comparing with C. 
albicans, it has been demonstrated their higher resistance to some antifungals such as 
fluconazole and itraconazole and their tendency to cause more severe or fatal diseases, 
especially in bloodstream infection cases (Shigemura et al., 2014).  
 
2.2.2.1 Candida glabrata 
 
The second causative agent of candidiasis is C. glabrata, whose infections present a 
mortality rate about 40%  (Fatahinia et al., 2020). It is a nosocomial pathogen that colonizes 
mucosal membranes and triggers challenging infections owing to their long hospitalization 
periods, high mortality rates and the emergence of resistance to azoles, echinocandins or 
multiple drugs (Khalifa et al., 2021).  
The fact of being a haploid yeast, in contrast to the diploid genome of C. albicans or 
other NAC spp.,  has been ascribed to the development of resistance to antifungal agents, as a 
single DNA repair mutation is enough to cause a related mutator phenotype and the subsequent 
emergence of resistance-conferring mutations (Healey et al., 2016). Although there is some 
evidence of pseudohyphae formation in this microorganism, its pathogenicity seems to be 
independent of morphology, as well as lower compared to C. albicans and strongly related to 
adhesion and flexibility (Galocha et al., 2019).  C. glabrata also forms biofilms, which increase 
mortality rates when placed on medical devices and show several differences comparing with C. 
albicans, for instance, C. glabrata biofilms are thinner, contain less biomass, have a different 
structure organization and are composed only by yeast cells. Nevertheless, they display a higher 
density of tightly packed cells. Regarding extracellular matrix, albeit being produced in a lesser 
extent than the one of C. albicans, they have the same main components: proteins and 





2.2.2.2. Candida auris  
 
Candidiasis infection deepens with the emergence of novel multidrug resistant (MDR) 
species of Candida genus such as C. auris, which was first described in 2009 when it was 
isolated from an ear discharge of a Japanese patient (Prasad, 2017). Since then, several reports 
of invasive infections and hospital outbreaks have appeared and it continues to spread unabated 
worldwide. Indeed, it is the only species having isolates resistant to all classes of human 
antifungal drugs (Pristov and Ghannoum, 2019). Unlike most Candida spp. which are mainly 
found in the gastrointestinal tract, C. auris is a colonizer of the skin (Lamoth et al., 2018).  
Four or possibly five clades of this nosocomial fungus have been identified in 
circulation while sequencing its whole genome. There is a high inter-clade genetic diversity 
represented by 40000-200000 single nucleotide polymorphisms (SNPs) differing from each 
other. Meanwhile, their intra-clade diversity is 17-fold lower, with differences of a mere 2-600 
SNPs between a given clade. Bearing this in mind, it is suggested that C. auris may have 
emerged independently in different parts of the world. By contrast, its local and international 
transmission is driven by some interconnected host-pathogen-environmental factors. Its 
emergence has been supported not only by the abuse of antimicrobials but also by several 
practices in agriculture, aquaculture, deforestation and land use, by the current warmer climate 
and by the changing human-population structure (Chakrabarti and Sood, 2021).  
The antifungal resistance machinery of C. auris, mostly based on mutations and 
overexpression of membrane transporters, is a substantial impediment to successfully 
managing its infections. The 90% of C. auris strains are resistant to fluconazole, resistance rates 
up to 30 % correspond to amphotericin B and although remaining still limited, echinocandin 
resistance has been reported alongside other antifungal resistance phenotypes too (Kean and 
Ramage, 2019). Also, in the research carried by Kean et al. (2018), 41% of the strains showed 
multidrug resistance and 4% demonstrate pan-resistance (Kean et al., 2018). Another of its 
defence mechanisms is biofilm formation, which resist all classes of antifungals attack. 
Biofilms sequester up to 90% of the drug in the extracellular matrix, express efflux pumps and 
contain persister cells (Chakrabarti and Sood, 2021). Eventually, C. auris also forms 
aggregative forms, which are more resilient and less virulent than non-aggregative strains and 
exhibit high azole resistance (Chakrabarti and Sood, 2021). Although several of its resistance 
mechanisms are analogous to those in other Candida spp., it is a challenge to fully understand 
its high-level resistance to antifungals and disinfectants. Some of the newest azoles such as 
posaconazole and isavuconazole have shown favourable results in vitro against this formidable 
yeast (Pristov and Ghannoum, 2019). 
 
2.3. Antifungal drugs 
 
Unlike the large battery of clinical antibacterial agents, the array of available 
antifungal drugs is somewhat scarcer due to the fact that the generation of new ones has fallen 
behind when compared to the fast pace of emergence of fungal infections. The main antifungals 
used for treating invasive candidiasis are azoles, polyenes, pyrimidine analogues and 
echinocandins, usually considering the last the first-line therapy. Their spectrum of activity and 




Table 1. Spectrum of activity and mechanisms of action and resistance of the major antifungal 
drugs against candidiasis. Some examples of the most commonly used drugs of each class are 





Azoles correspond to the largest class of antifungal compounds in clinical use, whose 
mechanism of action consists of binding and inhibiting the fungal cytochrome P450 enzyme 
14α-lanosterol demethylase (Erg11p), encoded by ERG11 gene, also known as CYP51. This 
enzyme catalyses an important step of ergosterol biosynthesis so its inhibition results in 
decreased membrane ergosterol content and the synthesis of a fungistatic toxic sterol (14α 















Inhibition of the fungal 
cytochrome P450 14α-
lanosterol demethylase 
(Erg11p) and accumulation 
of a toxic sterol resulting in 
growth inhibition. 
o Overexpression of Cdr1, 
Cdr2 and Mdr1.  
o Altered sterol import. 
o Target alteration or 
overexpression (ERG11, 
ERG3, ERG6, Upc2p). 
o Genomic alterations and 






Targeting ergosterol and 
creation of pores in the lipid 
bilayers leading to 
membrane disruption and 
cell death. 
o Mutations in ERG3 and 
ERG6. 
o High catalase activity 
leading to susceptibility to 
oxidative damage.  





Inhibition of DNA and RNA 
biosynthesis caused by the 
incorporation of fluorinated 
pyrimidine antimetabolites. 







Inhibition of β-(1,3)-glucan 
synthase and consequent 
decrease in the production of 
the major cell wall 
biopolymer β-(1,3)-glucan 
and loss of cell wall 
integrity. 
o Point mutations in hot 
spot regions of FKS1/2 
genes. 
o Genomic alterations.   
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elevation of reactive oxygen species (ROS) characteristic of azoles, are responsible of 
membrane disruption and growth inhibition (Bhattacharya, Sae-Tia, and Fries, 2020). Their 
action is fungistatic against most yeasts as Candida spp., but fungicidal against molds. Their 
import is energy-independent and has been proved to be via facilitative diffusion in some 
pathogenic fungi including C. albicans or C. krusei (Mansfield et al., 2010). 
Azoles are generally classified in two groups: imidazoles and triazoles. Imidazoles 
contain two nitrogen in the azole ring and include clotrimazole, econazole, ketoconazole, 
miconazole and tioconazole; while fluconazole, itraconazole, voriconazole, isavuconazole and 
posaconazole are triazoles with three nitrogen in the azole ring and comparing with imidazoles, 
display a broader antifungal spectrum with reduced toxicity (Prasad, 2017). Second generation 
of triazoles that comprises voriconazole, posaconazole and isavuconazole are more effective 
against resistant fungi (Bhattacharya et al., 2020). Fluconazole is the most commonly used and 
has a toxicity profile similar to that of isavuconazole, being the last more active (Wilson et al., 
2016). Besides, that novel azole is highly water soluble and differently from voriconazole, does 
not require beta-cyclodextrin in its intravenous formulation, consequently offering lower side 




Polyenes are a subgroup of macrolides that are poly-unsaturated and have at least one 
sequence of alternating double and single carbon-carbon bonds. Amphotericin B, nystatin and 
natamycin belong to this class of natural compounds with a heterocyclic amphipathic molecule. 
They are fungicidal and target ergosterol by inserting into the lipid bilayers and forming 
aqueous or nonaqueous (cation-selective) pores (Cohen, 2010). Thus, there is a leakage of 
monovalent ions (K+, Na+, H+ and Cl-) and subsequent fungal cell death.  
The topical use of Nystatin is thought to be the most common route of administration, 
although its spectrum of activity is narrower than the one of amphotericin B, which is 
considered the gold standard in the treatment of fungal, especially severe, infections (Costa-de-
oliveira and Rodrigues, 2020). However, it is unfortunately toxic to mammals. To reduce its 
toxicity, the conventional amphotericin B complexed with sodium deoxycholate has been 
modified as a cholesterol sulphate complex, as a lipid complex and as a liposomal formulation. 
Even if those reformulated versions have broad-spectrum activity against most fungi, their use 
is limited by their expensive cost. In addition, this drug is mainly preferred when tackling 
resistant Candida spp. to other antifungals (Bhattacharya et al., 2020). Regarding natamycin, it 
is specially chosen for the treatment of fungal keratitis and it is the only topical ophthalmic and 
potent drug with few side effects that has been approved by the Food and Drug Administration 
(Cui et al., 2021). Cui and co-workers have recently designed a promising drug delivery system 
with good biosafety and a significant anti-candidiasis effects consisting of nanoparticles for the 





2.3.3. Pyrimidine analogues 
 
The representative of this class of synthetic fluorinated analogues of cytosine is 5-
Flucytosine. It is orally administered and interferes with nucleic acid biosynthesis. Although it 
does not have intrinsic antifungal activity, once it is imported via the cytosine permease enzyme 
of susceptible fungal cells (Vermes et al., 2000), it is converted to 5-Fluorouracil by cytosine 
deaminase, which is then metabolized to 5-Fluorouridine triphosphate. This compound is 
incorporated in the fungal RNA, thereby inhibiting protein synthesis. Otherwise, 5-Flucytosine 
can also be converted to 5-Fluorodeoxyuridine monophosphate,  that inhibits thymidylate 
synthase and consequently DNA synthesis (Vermes et al., 2000).  
The spectrum of activity of pyrimidine analogues is restricted to pathogenic yeasts since 
most filamentous fungi are deprived of cytosine deaminase. It is preferable to use it in 
combination with other antifungal drugs rather than in monotherapy owing to its greatly 




Echinocandins are a relatively recent class of cyclic non-ribosomal antifungal 
lipopeptides produced by filamentous fungi. As a result of their complex structure, 
caspofungin, micafungin and anidulafungin are manufactured semisynthetically (Hüttel, 
2020). They target β-(1,3)-glucan synthase enzyme, encoded by FKS genes, located in the 
plasma membrane of fungal cells and responsible for the biosynthesis of the principal 
component of fungal cell walls: β-(1,3)-glucan. Thus, its inhibition results in loss of cell 
integrity. Moreover, the enzyme is composed of a minimum of two subunits: Fks1, the catalytic 
subunit, and Rho, a GTP-binding protein. However, some studies have revealed the presence of 
other membrane-associated components such as Pma1, which maintains transmembrane 
electrochemical proton gradients, and two other proteins of 40 and 18 kDa that may interact 
with the glucan synthase complex (Perlin, 2007). Against susceptible Candida spp., these 
antifungals showed in vitro fungicidal activity (Barchiesi et al., 2005). Simitsopoulou et al. 
(2013) proved that the three echinocandins are active against planktonic cells of all C. albicans, 
C. parapsilosis, C. lusitaniae C. guilliermondii and C. krusei strains as well as of biofilms of C. 
albicans and C. krusei bloodstream isolates. (Simitsopoulou et al., 2013). 
Nowadays, echinocandins are used as front-line therapy against invasive mycosis and 
are considered equivalent or even superior to the amphotericin B and fluconazole therapies 
(Patil and Majumdar, 2017). The absence of cell wall in mammalian cells makes that structure 
an important antifungal agent and the low toxicity for humans allows echinocandins to be 
commonly the treatment of choice.  
 
2.4. Mechanisms of resistance to antifungals 
 
Eukaryotic cells count on several non-exclusive mechanisms to protect themselves from 
xenobiotic compounds.  Their ability to survive at drug concentrations that exceed the minimum 
inhibitory concentration (MIC) is known as antifungal tolerance, which may promote the 
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acquisition of antifungal resistance. That resistance, on the contrary, show an increase of MIC 
values independent of the capacity to survive at drug concentrations beyond those MICs. It has 
been documented antifungal resistance to all currently available antifungal agents in several 
pathogens and in both laboratory and clinical settings (Delarze and Sanglard, 2015).  
Antifungal resistance has been classified in different types (Figure 1): primary or 
intrinsic, when it is manifested before antifungal exposure; secondary or acquired, which is 
exhibited after exposure to an antifungal agent, and can be either reversible in case of a 
transient adaptation or persistent as a consequence of one or more genetic alterations; and  
clinical resistance, that refers to the persistence or progression of an infection even when an 
appropriate antifungal therapy is being applied with an in vitro susceptibility of the organism 
(Costa-de-oliveira and Rodrigues, 2020).  
 
 
Figure 1. Classification of described antifungal resistance types.  
 
The emergence of multidrug resistance (MDR) phenomenon in yeasts has been 
developed by an inappropriate usage and prolonged exposure to those toxic compounds. It is 
characterized by simultaneous resistance to at least two different types of antifungals (Prasad et 
al. , 2019). 
 
2.4.1. Candida efflux pumps 
 
One of the most prominent mechanisms of antifungal resistance is the ability of C. 
albicans and NAC species to rapidly efflux incoming drugs via active transport (Prasad et al., 
2015). This mechanism arises from the overexpression of the two main classes of plasma 
membrane efflux pumps that can be also found in vacuolar membranes (Khandelwal et al., 
2019b) and mitochondrial membranes (Leighton and Schatz, 1995): the ATP-Binding Cassette 
(ABC) proteins, whose efflux is coupled with ATP hydrolysis, and the Major Facilitator 
Superfamily (MFS) transporters that utilize energy derived from proton motive force 
(Banerjee et al., 2021). Both classes are promiscuous transporters and they hamper the 
retention of detrimental concentrations of drugs inside the cells so that these can survive. In 
pathogenic fungi, including those of Candida genus, increased expression of these transporters 
correlates with azole resistance  (Bhattacharya et al., 2020). In terms of the amount of proteins 
involved in clinical azole resistance and the frequency of overexpression in resistant isolates, 
ABC superfamily contributes to that phenomenon in a wider extent (Holmes et al., 2016).  
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2.4.1.1. ABC transporters 
 
On the one hand, ABC proteins (Figure 2) are considered one of the largest 
superfamilies of proteins, specifically, in C. albicans a total of 28 putative ABC protein family 
members were identified (Gaur et al., 2005). In yeast species, aside from their role in drug 
transport, some of them also have physiological functions like vacuolar detoxification or metal 
ion, lipid and peptide transport (Kumari et al., 2021). They harbour at least one nucleotide 
binding domain (NBD) as energy source, each containing highly conserved motifs such as 
Walker A, Walker B and signature sequences. The hallmark of these transporters is their 
promiscuous nature that permit the efflux of many diverse substrates (Prasad et al., 2015).  
 
Figure 2. ABC protein representation (Cannon et al., 2009). 
 
According to the Human Genome Organization, these proteins can be clustered into six 
subfamilies designated ABCB/MDR, ABCC/MRP, ABCD/ALDP, ABCF/YEF3, ABCE/RLI 
and ABCG/PDR (Prasad et al., 2015). Since the members of ABCB/MDR, ABCC/MRP, 
ABCD/ALDP and ABCG/PDR subfamilies possess transmembrane domains (TMDs) that act as 
substrate recognition entities, they are regarded as ABC membrane-localized transporter 
proteins. Among them, proteins with one NBD and one TMD are considered half 
transporters, while those containing NBD and TMD in duplicate are known as full 
transporters and can be present in forward (TMD-NBD)2 or reverse (NBD-TMD)2 topology. 
Quite the contrary, the ABCF/YEF3 and ABCE/RLI representatives do not contain TMDs, 
hence they are nontransporter ABC proteins. After a rearrangement of the open reading 
frames by Candida Genome Database (CGD) assembly, the number of ABC proteins was 
reduced to 26 and 19 of them are ABC transporter proteins (Prasad et al., 2015).  
In all Candida species, ABCG/PDR subfamily is the largest, having 9 among 26 in C. 
albicans (Prasad et al., 2015), 7 among 25 in C. glabrata (Kumari et al., 2018), and 7 among 28 
in C. auris (Wasi et al., 2019). In C. albicans, four members of the PDR subfamily have been 
characterized, showing that Cdr1p (Candida drug resistance 1 protein) and Cdr2p (Candida 
drug resistance 2 protein) are the only involved in drug and phospholipids transport, and Cdr3p 
(Candida drug resistance 3 protein) and Cdr4p (Candida drug resistance 4 protein) translocate 
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phosphoglycerides between the two lipid monolayers of plasma membrane (Smriti et al., 2002;  
Sanglard et al., 1999). The increased expression in C. albicans of Cdr1p and Cdr2p in different 
drug-resistant clinical isolates proved that these transporters are the only involved in C. albicans 
clinical drug resistance (D Sanglard et al., 1995), although Cdr1p has been proved to contribute 
to a greater extent than Cdr2p to fluconazole resistance in C. albicans (Holmes et al., 2008). 
Despite the fact that only CaCdr1p and CaCdr2p are the only clinically relevant, there are others 
significant ABC transporters in C. albicans that are linked to azole resistance/sensitivity. 
Indeed, Cdr6/Roa1p has demonstrated to be an exporter of some xenobiotics and its deletion 
leads to hyperactivation of Tor1 and consequently, increased azole resistance (Khandelwal et 
al., 2018). Afterwards, the same group revealed the role of the vacuolar-membrane-localized 
ABC transporter Mlt1p in C. albicans importing azoles into vacuoles, that is to say, vacuolar 
sequestration (Khandelwal et al., 2019a).  C. albicans homolog CDR1 in C. auris is related to 
azole resistance, as well as the overexpression of CgCDR1, CgSNQ2, CgPDH1 and CgPDR16 
in C. glabrata (Bhattacharya et al., 2020).   
Cdr1p is a 169.9-kDa protein and full transporter with reverse topology. Each TMD is 
made up of six transmembrane helices (TMHs), which are interlinked by six extracellular loops 
(ECL1-6) and four intracellular loops (ICL1-4). In turn, the NBDs have the hallmark β-sheet 
sub-domain containing the Walker A and Walker B motifs and an α-helical sub-domain that 
consists of the conserved ABC signature sequence (Prasad et al., 2015). Regarding 
polyspecificity, Cdr1p has a wide range of structurally unrelated molecules as substrates, whose 
features are high hydrophobicity, molecular branching, high aromatic and the presence of an 
atom-centered fragment (R-CH-R) (Puri et al., 2010). Some of these substrates are antifungals, 
fluorescent dyes, plant products, herbicides, anticancer drugs, steroids and phosphoglycerides 
(Prasad et al., 2015). In order to understand the molecular basis of polyspecificity in CaCdr1p 
and unveil the location of its drug binding site, Rawal and co-workers (2013) employed alanine 
scanning mutagenesis. That study revealed the presence of multiple overlapping minibinding 
sites within a polyspecific substrate binding site and some critical residues in the TMDs that, 
likewise the substrates of this efflux pump, were mainly hydrophobic in nature. Of note, the 
importance of a residue in substrate binding or transport and its degree of conservation did not 
directly correlate (Rawal et al., 2013).  The main reason of this polyspecificity seems to be the 
primary sequence variation of TMDs (Banerjee et al., 2021). 
Concerning regulation, the transcription of CDR1 is controlled by several well-
characterized trans factors such as TAC1, which is often associated with gain-of-function 
mutations that lead to hyperresistance in clinical Candida isolates (Coste et al., 2006). There are 
other factors like UPC2, that is involved in sterol biosynthesis, acts as an activator or repressor 
depending on its own activation and the upc2∇/∇ cause azole hypersusceptibility; or the bZIP 
transcription factor coded by CAP1 gene (Prasad et al., 2015). Zinc-cluster transcription factors 
were analysed using artificial activation by fusion of the C terminus of the protein with the 
heterologous Gal4 activation domain. This method helped in the characterization of the 
multidrug resistance regulator MRR2 as mediator of fluconazole resistance through 
overexpression of CDR1 (Schillig and Morschhäuser, 2013). Additionally, CDR1 promoter has 
some regulatory elements including AP-1, yeast AP-1 (YAP-1), heat shock elements (HSEs) 





2.4.1.2. MFS transporters  
 
On the other hand, the ubiquitous MFS transporters (Figure 3), abundant in Candida 
spp., can act as uniporters, antiporters and symporters (Banerjee et al., 2021). In C. albicans, 
95 members of MFS group have been identified, divided in 17 families among which Drug: H+ 
Antiporter-1 (DHA1) and Drug: H+ Antiporter-2 (DHA2) are the major families with 22 and 
9 representatives respectively (Manisha Gaur et al., 2008).  
 
Figure 3. MFS protein representation (Cannon et al., 2009). 
 
Conjointly with CaCdr1p and CaCdr2p, CaMdr1p is the only multidrug transporter of 
this family showing clinical significance (Prasad et al., 2017). However, CaFlu1p has 
experimentally demonstrated to confer azole resistance albeit not contributing to clinical drug 
resistance (Calabrese et al., 2000).  Mdr1p, formerly known as BENr for benomyl resistance 
(Banerjee et al., 2021), is a typical DHA1 subfamily antiporter that contains 12 TMHs, five 
ICLs, six ECLs, an “antiporter motif” within TMH5, a large ICL3 considered as the central 
cytoplasmic loop or CCL and a long hydrophilic N-terminal extension whose importance is yet 
to be clarified  (Redhu et al., 2016; Pasrija et al., 2007; Banerjee et al., 2021). In C. glabrata, 
the transporters clinically significant are CgFLR1 and CgQDR2, whose increased expression is 
associated with azole-resistant clinical isolates (Bhattacharya et al., 2020). Similar to the study 
of Rawal et al. (2013) on CaCdr1p, Redhu et al. also performed alanine scanning mutagenesis 
for all the residues present within the TMDs of CaMdr1p (Redhu et al., 2018). Around 33% (84 
out of 252) of the variants showed total or selective loss of drug resistance, and of those, 53 
were sensitive to all of the tested drugs and the rest were sensitive to at least one (Redhu et al., 
2018). In addition, apart from CaMdr1p TMH4, which resulted to be maximally conserved and 
have the maximal number of critical residues, no direct relationship was detected between the 
TMH conservation and their functional importance (Redhu et al., 2018). This study also 
provided some insight about Mdr1p broad substrate promiscuity, revealing that the structural 
basis for polyspecificity is conferred by certain residues situated at the periphery of the central 
core that can accommodate compounds of different size or type (Redhu et al., 2018). 
The multidrug resistance regulator, MRR1, is the transcription factor responsible for 
MDR1 expression and the gain of function in Mrr1p, followed by loss of heterozygosity, 
represents the principal cause of MDR1 overexpression in C. albicans strains resistant to 
fluconazole (Dunkel et al., 2008).  
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2.4.1.3. Impact of efflux pumps on cell functioning 
 
The potentially high operational cost of these efflux pumps brings up to the question of 
whether they interfere with cell functioning. Indeed, while these transporters prevent cells from 
being attacked by toxic compounds, on the contrary, their excessive activity can compromise 
the overall cellular fitness under normal conditions (Knorre et al., 2020).  Firstly, activity of 
MDR transporters is linked to an energy expenditure due to basal ATP-hydrolysing, which is 
not stimulated by the addition of substrates (Ernst et al., 2008). Secondly, it can compromise 
plasma membrane properties such as ergosterol content under stress conditions or sterols 
distribution, since MDR transporters contribute to plasma membrane lipid asymmetry, 
consequently being involved in the maintenance of lipid homeostasis (Knorre et al., 2020). 
Also, MDR transporters can promote unintentional efflux of some natural metabolic 
intermediates, thus decreasing metabolic efficiency; and cell-to-cell communication 
disturbance because of an excessive efflux of quorum-sensing factors. Zhu et al. (2011) 
showed for the first time the involvement in C. albicans of Cdr1p-mediated glutathione efflux 
as a mechanism preceding the farnesol-induced apoptotic process. Farnesol, a quorum-sensing 
molecule in C. albicans, conjugates with glutathione, a crucial antioxidant for cellular 
detoxification, and the resulting conjugates act as substrates of ABC transporters, finally leading 
to oxidative stress and fungal cell death (Zhu et al., 2011).  
 
 2.4.2. Other mechanisms of resistance  
 
2.4.2.1. Entry constraints  
 
There are several hypotheses of defective azole entry that could contribute to drug 
resistance reducing intracellular azoles. However, there is still no evidence of identified azole 
importers and their roles in azole resistance (Bhattacharya et al., 2020). Where we have clear 
evidence is in the mechanism of sterol import that reduces the need for sterol biosynthesis and 
thus compensates the effect of azoles decreasing the content of ergosterol.  This mechanism has 
been well characterized in the human fungal pathogens C. albicans and C. glabrata, showing 
some differences between them (Zavrel et al., 2013). C. glabrata can uptake sterols either in 
aerobic or anaerobic conditions and the limited aerobic import can be stimulated by the presence 
of serum with fluconazole; whereas in C. albicans the mechanism only occurs in aerobic 
conditions, increasing azole resistance in the presence of both serum and cholesterol (Zavrel et 
al., 2013). Bearing this in mind, it can be stated that C. albicans could develop azole resistance 
by importing cholesterol and serum from the blood (Bhattacharya et al., 2020). 
 
2.4.2.2. Genomic alterations  
 
 Given that azoles target ergosterol, altered biosynthesis of that component is an 
essential mechanism of resistance. ERG11 overexpression has been linked to azole resistance 
in many fungi, including C. albicans, C. glabrata and C. auris (Bhattacharya et al., 2020). 
Besides, azole resistance can be acquired by mutated versions of ERG11 mutations like A61V, 
A114S, Y132F, Y132H, K143Q, K143R, Y257H, S405F, G448E, F449S, G464S, R467K and 
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I471T in C. albicans (Xiang et al., 2013). Point mutations in that gene have also been identified 
in other azole-resistant Candida spp. like C. glabrata mutations C108G, C423T and A1581G; 
and C. krusei mutations A497 and G1570A (dos Santos Silva et al., 2016). When azoles inhibit 
Erg11p, Erg3p and Erg6p synthesize the toxic sterol. Disruption of ERG3 increases azole 
resistance in C. albicans (Sanglard et al., 2003), just as heterozygous ERG6 deletion (Yoo et al. 
, 2010). Upc2p regulates the majority of ergosterol biosynthetic genes, among which we find 
ERG11. Mutations G648D, G648S, A643T, A643V, Y642F, A646V and W478C in CaUpc2p 
exhibited increased expression of ERG11 and increased resistance to fluconazole (Flowers et 
al., 2012). In C. glabrata, deletion of CgUPC2A, one of the two homologues of CaUPC2, has 
been linked to azole susceptibility (Nagi et al., 2011).   
 In addition to azoles, there are target alterations causing resistance to other drugs. 
Polyene resistance, despite not being well characterized, is associated with changes in ERG3 
and ERG6 genes (Bhattacharya et al., 2020). Whilst still quite unusual, resistance to 
amphotericin B can be mediated by a higher catalase activity and a consequent decrease in 
oxidative damage susceptibility (Costa-de-oliveira and Rodrigues, 2020).  
Point mutations in FKS genes, which encode echinocandins’ target β-(1,3)-glucan 
synthase, hold relevance in echinocandin resistance. Mutations in the catalytic subunit of that 
enzyme, FKS1 gene, contribute to a higher extent than mutations in FKS2 gene, both leading to 
amino acid substitutions in two different regions of these genes (Hot spot 1 and 2, or HS1 and 
HS2) (Costa-de-oliveira and Rodrigues, 2020). In C. albicans, where therapeutic failure still 
occurs rarely, amino acid substitutions at Ser645 and Phe641 are the most pronounced 
phenotypes, accounting for more than 75% of resistance in that species; while in C. glabrata, 
where resistance is rising, are Ser629, Ser663 and Fks2 position F659S (Perlin, 2015). 
Eventually, C. auris isolates initially susceptible to echinocandins can develop de novo FKS1-
mediated resistance after echinocandin exposure (Prasad et al., 2019). 
With regard to resistance to 5-Flucytosine among Candida, it is associated with 
mutations in the enzyme uracil phosphoribosyl transferase (Fur1p) that unable the conversion 
of 5-fluorouracil to 5-fluorouridine monophosphate (Costa-de-oliveira and Rodrigues, 2020). 
Furthermore, mutations in FCY1 and FCY2 genes have been related to 5-Flucytosine resistance 
in some Candida spp. like C. auris, C. lusitaniae or C. glabrata (Frías-De-León et al., 2020; 
Florent et al., 2009; Edlind and Katiyar, 2010). 
Genomic plasticity seems to be a conserved and central adaptative mechanism of 
resistance (Revie et al., 2018). In fungi, azole resistance is correlated with aneuploidy and loss 
of heterozygosity (LOH), in which the mutation of one allele can be copied to the second 
(Bhattacharya et al., 2020). LOH in CaTAC1, CaERG11 and CaMRR1 have been correlated 
with increased levels of resistance (Ford et al., 2015). Also related with major azole resistance, 
clinical isolates of C. albicans have shown segmental aneuploidy, in which two copies of the 
left arm on chromosome 5 containing CaERG11 and CaTAC1 form an isochromosome 
(Selmecki et al., 2006); trisomy in chromosome 4 (Anderson et al., 2017), whose mechanism of 
resistance is still unknown; loss of one homologue of chromosome 4, aneuploidy in 
chromosome 6 and trisomy in chromosome 3 (Bhattacharya et al., 2020). Further, trisomy in 
chromosome R contributes to azole resistance too (Li et al., 2015). In C. glabrata, aneuploidy 
and alteration in gene copy numbers have been associated with high levels of azole resistance 
(Bhattacharya et al., 2020). Recently, transient duplication in CDR1 and ERG11 genes in 
generationally aging C. auris cells cause increased tolerance to fluconazole (Bhattacharya et al., 
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2019). Even though its mechanism has not been studied deeply, chromosome 2 trisomy in C. 
albicans causes caspofungin resistance (Bhattacharya et al., 2020).   
In some cases, genomic alterations comprising the generation of an isochromosome, 
are an alternative way to enhance antifungal efflux and thus resistant traits in Candida species. 
It has been observed a duplication of the left arm of chromosome 5 (i(5L)) as a common 
aneuploidy in C. albicans azole-resistant isolates, leading into an increased dosage of both 
ERG11 and TAC1, hence enabling a dual mechanism of azole resistance (Revie et al., 2018).  
 
2.4.2.3. Cell plasticity 
 
Cell plasticity is another contributor to antifungal resistance, mainly the extracellular 
matrix of biofilms that promotes adherence and protection from hostile environmental 
conditions. In fact, biofilm production by C. albicans confer up to a 1000-fold greater drug 
resistance compared with non-biofilm cells in vitro (Pristov and Ghannoum, 2019). C. albicans 
biofilms are resistant to azoles and conventional amphotericin B, while liposomal 
amphotericin B and echinocandins are effective upon them  (Costa-de-oliveira and Rodrigues, 
2020).  
Besides, in some Candida species, in particular C. albicans, there is an alternative 
respiratory pathway corresponding to an alternative oxidase (AOX). It has been implicated in 
reduced susceptibility to azoles through a mechanism in which exposure to antifungal agents 
decrease intracellular reactive oxygen species (ROS) production (Yan et al., 2009). Inhibition of 
this alternative pathway leads to enhanced recognition by macrophage cells but when that 
inhibition is removed, a stress response takes place increasing the levels of virulence traits 
(Duvenage et al., 2019). 
 
2.5. Cellular stress responses mediating resistance 
 
Antifungal exposure is one of the stressing conditions under which Candida cells 
activate several cellular stress response pathways. Firstly, the cyclic AMP (cAMP)-protein 
kinase A (PKA) signalling pathway is often involved in the stress responses mediating 
triazole resistance. In C. albicans, it contributes to the recovery process facilitating the resume 
of growth after stress conditions or fluconazole exposure (Costa-de-oliveira and Rodrigues, 
2020).  Secondly, another cellular response is the Ca2+-calmodulin-calcineurin pathway. 
Calcium acts as a secondary messenger molecule in both mammals and fungi, regulating 
cellular processes and playing crucial roles in cell survival. In conjunction with mainly 
calcineurin and other components of the fungal calcium signalling pathway, they can mediate 
antifungal resistance of invasive fungal strains (Liu et al., 2015). Therefore, they could be seen 
as targets for new therapies. Particularly against candidemia, Jia et al. (2012) found that 
calcium-activated-calcineurin can severely reduce the efficacy of fluconazole treatment both in 
vitro and in vivo through its target Rta2p and the transcription factor CRZ1 (Jia et al., 2012). 
Calcineurin is stabilized by the molecular chaperone heat shock protein 90 (Hsp90), giving way 
to cellular stress responses that are required for echinocandin resistance. Actually, calcineurin 
may be defined as the key mediator of Hsp90-dependent echinocandin resistance (Singh et al., 
2009). A previous work of the same group stated the genetic reduction of Hsp90 levels in a 
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murine model of disseminated C. albicans infection enhances the efficacy of fluconazole 
activity (Singh et al., 2009).  
Furthermore, most Candida species have shown the potential of increasing chitin 
synthesis as a mechanism of tolerance to echinocandins, as cells with high chitin content are 
less susceptible to caspofungin (Walker et al., 2013). Echinocandin tolerance has also been 
related to the C. albicans transcription factor CAS5, which makes echinocandin resistance 
possible in a FKS1-mutated strain (Xie et al., 2017). 
 
2.6. Strategies to overcome antifungal resistance and tolerance  
 
Owing to the alarming life-threatening infections caused by Candida spp., it is vital to 
find new strategies so that we could reduce drug resistance.  
 
2.6.1. Inhibition of efflux 
 
An approach that has attracted significant attention after the growing incidence of 
resistant Candida isolates is the structure-based design of effective inhibitors of efflux 
(Figure 4). These can affect pumps directly, either by binding as a pseudosubstrate and blocking 
access to the binding site, or by locking the drug in a conformation so that efflux reaction cycle 
is impeded (Cannon et al., 2009). Unfortunately, the lack of high-resolution structures for yeast 
PDR pumps and the incomplete understanding of the mechanisms required for efflux pump 
inhibition and modulation hinder the implementation of these inhibitors into the clinic (Banerjee 
et al., 2021).  
Some inhibitors with potential that have been identified are the immunosuppressant 
FK520, clorgyline, jatrophanes, curcumin, disulfiram inhibiting the oligomycin-sensitive 
ATPase activity of Cdr1p, farnesol acting as modulator of the same transporter and some 
peptide and peptide-derivatives including the D-octapeptide derivative RC21v3 (Prasad et al., 
2015; Prasad et al., 2019). Unlike CaCdr1p, only few molecules are able to inhibit CaMdr1p so 
far. For example, clorgyline, certain chalcones, jatrophanes or lathyrane diterpenes (Prasad 
et al., 2019).  
The development of indirect inhibitors of efflux is also considered in that context. 
They would act depriving cells of the energy required for drug efflux by lowering the 
cytoplasmic ATP concentration or by depleting the electrochemical potential of the plasma 
membrane (Cannon et al., 2009). Proton pump inhibitors, combined with fluconazole, 
enhance the efficacy of that azole both in vitro and in vivo. Moreover, the synergistic antifungal 
effects lead to efflux pump activity suppression and some Candida virulence factors inhibition, 









  Figure 4. Direct and indirect inhibition of efflux pumps (Cannon et al., 2009).  
 
2.6.2. Chemosensitization  
 
In the study of chemosensitizers, it has been reported that FK506 and cyclosporine A 
(CsA) chemosensitize C. albicans cells to azoles, inhibiting calcineurin and turning the 
spectrum of activity of those drugs to fungicidal (Costa-de-oliveira and Rodrigues, 2020). 
Though being both immunosuppressive is a disadvantage when it comes to treat candidiasis 
patients, who are already immunocompromised. Furthermore, calcium channel blockers such 
as amlodipine, nifedipine, benidipine and flunarizine can increase the sensitivity of fluconazole 
to resistant C. albicans strains (Liu et al., 2016); and transmembrane peptide mimics 
(TMPMs) of efflux pumps have the ability to chemosensitize CaCdr1 overexpressing clinical 
isolates toward fluconazole (Prasad et al., 2019; Maurya et al., 2013). The synergistic 
relationship between sulfa antibacterial drugs and fluconazole has been studied in C. albicans, 
as well as it has been confirmed the ability of these drugs to inhibit Candida biofilms by 40% 
(Eldesouky et al., 2018). However, it has been reported that antibacterial agents administration 
can unbalance the fungal microbiome and consequently increase colonization and proliferation 
of yeasts (Costa-de-oliveira and Rodrigues, 2020). 
Therapies based on the combination of drugs can also play a key role potentiating 
antifungal action and leading to shorter treatment periods, lower doses of drugs and higher 
efficiency of single agents. Nim et al. (2018) found that chalcone derivatives 
diphenylpropenones combined with fluconazole act as antifungal sensitizers by antagonizing the 
drug efflux pump activity of CaCdr1p and CaMdr1p (Nim et al., 2018). Among the different 
derivatives assessed by Nim and co-workers, four compounds were able to sensitize yeasts 
overexpressing both transporters, were not considered cytotoxic to yeast cells and were easily 
synthesized. Everything together underlines their potential to undergo further development for 
preclinical trials to make azoles active again (Nim et al., 2018).   
 
2.6.3. Design of new antifungal drugs 
 
Currently, one of the routes for designing new drugs is on a styrylquinoline scaffold. In 
2017, it came to light the first evidence that styrylquinolines, heterocyclic and lipophilic 
compounds,  decrease the activity of ABC multidrug transporters and act synergistically with 
fluconazole (Szczepaniak et al., 2017). More recently, it has been revealed that metal 
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complexation through hydroxyl groups could be the mechanisms of action of styrylquinolines 
and that synergistic interactions are reliant on the substitution pattern (Cieslik et al., 2020). 
Styrylpyridinium compounds, initially synthesized as fluorescent probes, are 
promising drug candidates too. Vaitkienė and her group lately demostrated the antifungal 
activity of a set of new and earlier described styrylpyrydinium compounds against C. albicans 
cells and evaluated their possible synergism with fluconazole (Vaitkienė et al., 2020a). Eight 
out of thirteen reduced C. albicans growth and some of them were considered substrates of C. 
albicans MDR pumps. The compound with a NEt2 group as substituent showed the strongest 
fungicidal properties, effectively inhibiting respiration but possessing the highest toxicity to 
mammalian cells. Nonetheless, the most active synthesized styrylpyridinium compound was 4-
(4-cyanostyryl)-1-dodecylpyridin-1-ium (CSDP+) bromide with a CN-group as substituent. It 
presented at fungicidal concentrations the least toxicity to mammalian cells, the most effective 
synergism with fluconazole and a strong inhibition of the growth and respiration of C. albicans 
(Vaitkienė et al., 2020a).  
Later, it was evaluated the interaction of  low concentrations of CSDP+ bromide with 
yeast and mammalian cells, resulting in an absence of toxicity to HEK-293 cells and a reduction 
of C. albicans adhesion, both alone and in combination with fluconazole (Vaitkienė et al., 
2020c). Preventing adhesion was such an encouraging result, as it is a crucial factor for 
colonization and persistence of the pathogen. This study also suggests the possible association 
of the expression of MDR1 and MRR1 genes in C. albicans with fluconazole resistance related 
efflux, as they are overexpressed after the exposure to that antifungal in combination with 
CSDP+ (Vaitkienė et al., 2020c). 
On the basis of the highest efficiency against C. albicans, Vaitkienė and colleagues 
selected and evaluated eight styrylpyridinium compounds from their previous study (Vaitkienė 
et al., 2020a) on C. glabrata strains containing or not drug efflux pumps (Vaitkienė et al., 
2020b). Their mechanism of action, based on permeabilization of the plasma membrane, 
resulted to be dependent on their structure, exposure time and concentration. All compounds 
were exported from C. glabrata cells as substrates of their MDR pumps, mainly Cdr1p, so they 
could be properly applied in combined therapy by increasing the concentration of another 
antifungal drug above the effective threshold due to binding site competition. Their potential 
was also emphasised with their large Stokes shifts and small overlaps between the absorption 
and fluorescence spectra. Ultimately, styrylpyridinium compounds may be applied not only as 
new antifungal drugs, showing significant synergism with FK506 and terbinafine, but also as 
fluorescence dyes with low toxicity in yeast research (Vaitkienė et al., 2020b).  
 
2.6.4. Other strategies 
 
The first approach that come to mind in order to bypass drug resistance due to efflux 
pumps would be the research on antifungals that are not substrates of them (Figure 5), like 
echinocandins or amphotericin B (Costa-de-oliveira and Rodrigues, 2020). That could be 
possible taking into account size and hydrophobicity constraints, at the same level as 
complicated since efflux pumps have developed flexible and large drug-binding sites  (Cannon 
et al., 2009). Otherwise, focusing on a promotion of antifungal uptake (Figure 6) may 
promote the maintenance of high intracellular concentrations of antifungal in spite of any 
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upregulation of efflux. Inclusion of multiple arginine residues in antifungals would enhance 











More combination therapies have shown promising results. In a murine model of 
systemic infection caused by C. albicans, the very well-known anti-inflammatory drug 
ibuprofen exhibited a synergistic effect with fluconazole against fluconazole-resistant strain 
(Costa-de-Oliveira et al., 2015); the combination of the peptidyl nucleoside Nikkomycin Z with 
caspofungin and micafungin demonstrated to be synergic in C. albicans biofilms (Kovács et al., 
2019); and a synergistic effect in C. albicans fluconazole resistant strains was exhibited by the 
flavonoid kaempferol (Shao et al., 2016). More flavonoids have been studied in the field of 
novel therapeutic approaches. For instance, selected flavones (luteolin, apigenin), flavonols 
(quercetin), and their glycosylated derivatives (quercitrin, isoquercitrin, rutin and apigetrin), 
have shown antifungal capacity not only reducing biofilm and hyphal formation but also, 
lowering the expression of the resistance linked genes CDR1 and ERG11 (Ivanov et al., 2020). 
This year, a study analysing a wide range of antifungal combinations against echinocandin-
resistant and echinocandin-susceptible C. glabrata has confirmed that most of the synergistic 
action takes place among the echinocandin-resistant isolates (Khalifa et al., 2021). For the first 
time, it has been discovered a sustained fungicidal activity against an echinocandin-resistant 
isolate by the synergistic action of caspofungin-fluconazole, caspofungin-voriconazole, 
caspofungin-posaconazole, and 5-flucytosine-amphotericin B combinations, with 
caspofungin-voriconazole and 5-flucytosine-amphotericin B combinations (Khalifa et al., 
2021). 
Further, other prospects for resistance prevention would be the identification of the 
molecular mechanisms behind biofilm state or adherence that could pave the way for new 
biofilm-specific therapeutics (Nobile and Johnson, 2015) and targeting the stress-response 
components that permit tolerance and development of resistance. Compromising Hsp90 
function in vitro enhances the efficacy of echinocandins against isolates that evolved resistance 
in a human host and isolates not previously exposed to these drugs (Singh et al., 2009). 
Additionally, an overview of the components of the fungal calcium-calcineurin signalling 
pathway and their potential roles as antifungal targets would be convenient for the development 
of new antifungal drugs. Interestingly, on account of the deleterious effects of excessive MDR 
transporters activity, cells keep MDR pumps genes repressed under normal conditions, activate 
them only upon exposure to chemical stress and their basal expression can vary with changes in 
Figure 5. Use of antifungals that are not 
substrates of efflux pumps (Cannon et 
al., 2009).    
Figure 6. Promotion of antifungal 




the metabolic state of the cells. Notwithstanding, this can make cells vulnerable to hypothetical 
toxins that could avoid detection inside the cells and do not activate MDR transporters. 
Therefore, studying this approach may be a promising strategy in the research of new efficient 
antifungals (Knorre et al., 2020). 
 
3. CONCLUSIONS AND RECOMMENDATIONS  
 
1. Scientific information from different databases has been obtained, including 
PubMed, ScienceDirect, Google Scholar and Scopus. From science journals 
including Nature and Science; and from web pages and books available on Internet. 
There is a clear agreement in the information provided and, especially, in the 
relationship between Candida infections and colonization of those pathogens in the 
medical setting. To prevent outbreaks and collapse of the health system, surface 
disinfection in hospital rooms and finding ways to decolonize serious pathogens 
such as C. auris should be emphasised.  
 
2. Cryo-electron microscopy, pharmacophore-based screening and other 
bioinformatics technologies are worth of further application in studies of the most 
clinically important Candida efflux pumps. Their functioning could be completely 
understood with the availability of more data on 3D structures.  
 
3. The actual COVID-19 pandemic has promoted an unforeseen and unavoidable 
increase in antifungal resistance. It should be pointed out the high rate of 
antimicrobial agent use in COVID-19 patients with relatively low rates of co-
secondary infections. That brings up to the urgent need of effective antifungal 
stewardship programme, comprising quicker fungal diagnostics, appropriate 
prescription of antifungals, therapeutic drug monitoring and clinical intervention 
teams to control resistance.  
 
4. In spite of the fact that many strategies are being devised to avoid resistance, 
identification of innovative fungal targets and exploration of multiple targeting 
therapies are being underrated in the antifungal drug discovery. Exploiting these 
challenges with the help of in silico investigations may provide a substantial impact 
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